证券代码：301258 证券简称：富士莱 公告编号：2025-029 苏州富士莱医药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 特别提示： 1、截至本公告披露日，苏州富士莱医药股份有限公司（以下简称"公司"或 "本公司"）总股本为 91,670,000 股，回购专用证券账户中持有 880,000 股，根据 《公司法》的规定，已回购的股份不享有本次利润分配权利。故本次实际参与权 益分派的股本基数为 90,790,000 股，向全体股东每 10 股派 0.910000 元人民币现 金（含税，小数点后保留六位，下同），合计派发现金红利 8,261,890.00 元，不 送红股，不以资本公积转增股本。 2、根据公司 2024 年度利润分配方案，按公司总股本（含回购股份）折算每 10 股现金红利如下：每 10 股现金红利（含税）=现金分红总额/总股本（含回购 股份）×10 股=8,261,890 元/91,670,000 股×10 股=0.901264 元。 本次权益分派实施后的除权除息参考价格=股权登记日收盘价-按总股 ...

Market Overview - As of May 27, the Shanghai Composite Index closed at 3340.69 points, down 6.15 points, a decrease of 0.18% [1] - The Shenzhen Component Index closed at 10029.11 points, down 62.05 points, a decrease of 0.61% [1] - The ChiNext Index closed at 1991.64 points, down 13.62 points, a decrease of 0.68% [1] High Turnover Stocks - A total of 106 A-shares had a turnover rate exceeding 20% on May 27, with four stocks, including Xintiandi and Wangzi New Materials, exceeding 50% turnover rate [1] - The stock with the highest turnover rate was Xintiandi (301277) at 62.93%, closing at 16.41 yuan with a price increase of 14.12% [1] - Wangzi New Materials (002735) had a turnover rate of 54.67%, closing at 18.81 yuan with a price increase of 2.67% [1] - Other notable stocks with high turnover rates include Snowman Co. (002639) at 53.93% and Rich Intelligent Manufacturing (833781) at 52.80% [1] Additional High Turnover Stocks - Other stocks with significant turnover rates include: - Haisan Pharmaceutical (001367) at 48.22%, closing at 23.94 yuan, down 7.21% [1] - Shengye Electric (920128) at 45.79%, closing at 39.30 yuan, up 0.13% [1] - Zhenghe Ecology (605069) at 45.16%, closing at 11.20 yuan, unchanged [1] - Tianyuan Pet (301335) at 40.22%, closing at 38.75 yuan, down 2.15% [1] - Hahai Huaton (301137) at 38.47%, closing at 39.59 yuan, up 20.01% [1] Summary of Notable Stocks - The following stocks also had notable turnover rates: - New Jinlu (000510) at 36.97%, closing at 6.27 yuan, up 6.09% [1] - Zhihai Technology (300771) at 36.72%, closing at 12.69 yuan, down 1.63% [1] - Hongqiang Co. (002809) at 36.41%, closing at 15.30 yuan, up 6.55% [1] - Zhongzhou Special Materials (300963) at 35.69%, closing at 34.87 yuan, up 1.31% [1] - Xinbang Intelligent (301112) at 35.66%, closing at 40.04 yuan, down 0.55% [1]

证券代码：301258 证券简称：富士莱 公告编号：2025-028 苏州富士莱医药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 特别提示： 1.本次股东大会不存在否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 （一）会议召开的时间 1、现场会议时间：2025 年 5 月 16 日下午 14:30。 2、网络投票时间：2025 年 5 月 16 日 （1）通过深圳证券交易所交易系统进行网络投票的时间为： 2025 年 5 月 16 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 5 月 16 日 9:15-15:00。 （二）现场会议召开地点：江苏省常熟市新材料产业园海旺路 16 号 （三）股权登记日：2025 年 5 月 12 日（星期一） （五）股东大会的召集人：公司董事会 （六）会议主持人：董事长钱祥云先生 （七）会议的召集、召开与表决程序符合《公司法》《上市 ...

上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 2024 年年度股东大会的 法律意见书 地址：苏州市姑苏区人民路 3110 号国发大厦南楼 907 电话：0512-67872033 关于苏州富士莱医药股份有限公司 上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 关于苏州富士莱医药股份有限公 司 2024 年年度股东大会的 法律意见书 致：苏州富士莱医药股份有限公司 上海兰迪（苏州）律师事务所（以下简称"本所"）接受苏州富士莱医药股份有 限公司（以下简称"公司"）的委托，就贵公司召开的 2024 年年度股东大会（以下 简称"本次股东大会"）进行见证并就相关事宜出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以 下简称"《股东大会规则》"）、《深圳证券交易所上市公司股东大会网络投票实施 细则》以及《苏州富士莱医药股份有限公司章程》（以下简称"《公司章程》"）等 规定，就本次股东大会的召集和召开程序、召集人资格和出席会议人员资格、会议表 决程序和表决结果等相关事 ...

Core Viewpoint - The company held an online performance briefing for 2024 and Q1 2025, addressing concerns about declining revenue and net profit due to increased competition and price drops in the market for lipoic acid products [1][2]. Revenue and Profit Decline - The company reported a revenue of 429.468 million yuan for 2024, a decrease of 12.23% year-on-year, and a net profit attributable to shareholders of 16.4061 million yuan, down 85.38% year-on-year [3]. Product Performance - The company noted a stable market demand for lipoic acid series products in 2024, with a 21.35% year-on-year increase in the shipment volume of granular lipoic acid, despite prices not showing significant recovery [3]. New Product Development and Business Expansion - The company has received approval for the active pharmaceutical ingredient (API) of Apatinib and plans to focus on specialty APIs, CMO/CDMO expansion, and new product development [4]. - The company is investing in R&D for specialty APIs and has initiated five API projects in 2024, with some projects already completing initial testing [4]. Other Key Points - The construction of the Shandong branch is expected to take 30 months, with completion aimed for June 2026, and will include multiple production lines for specialty APIs and intermediates [5]. - Approximately 9% of the company's revenue in 2024 is expected to come from direct exports to the U.S., with close monitoring of tariff policy changes [5].

Core Insights - Fujilai (SZ301258) reported a significant decline in financial performance for the year 2024, with total revenue of 429.47 million yuan, a decrease of 12.23% compared to 2023 [1][2] - The net profit attributable to shareholders dropped to 16.41 million yuan, reflecting an 85.38% decline year-on-year [1][2] - The company experienced a substantial loss in net profit after deducting non-recurring items, amounting to -8.92 million yuan, a decrease of 109.96% [1][2] Financial Performance - Total revenue for 2024 was 429,468,011.82 yuan, down from 489,292,586.96 yuan in 2023, marking a 12.23% decline [2][3] - Net profit attributable to shareholders was 16,406,148.23 yuan, compared to 112,181,787.31 yuan in 2023, a decrease of 85.38% [2][3] - The net profit after deducting non-recurring items was -8,924,873.45 yuan, down from 89,606,898.67 yuan in 2023, indicating a decline of 109.96% [2][3] - Operating cash flow net amount was 47,068,013.45 yuan, a decrease of 50.33% from 94,768,588.39 yuan in 2023 [2][3] Revenue Breakdown - Revenue from external sales was 211.23 million yuan, a decline of 31.39%, while domestic sales revenue increased by 20.31% to 218.24 million yuan [2][3] - Sulfuric acid series revenue was 276.48 million yuan, down 26.25% year-on-year [2][3] - The revenue from the raw material drug, Arixib, surged by 835.06% to 62.98 million yuan [2][3] Product and Business Segmentation - The pharmaceutical main business accounted for 99.19% of total revenue, with a total of 426,006,805.49 yuan, down 11.82% from the previous year [3] - The sulfuric acid series products contributed 64.38% of total revenue, while the phosphatidylcholine series and the dipeptide series accounted for 9.57% and 10.58%, respectively [3] - Other business segments saw a significant decline of 44.10%, contributing only 3.46 million yuan to total revenue [3] Company Leadership - The chairman of Fujilai is Qian Xiangyun, who has been in the role since August 2008 and has a background in various positions within the company and local government [4] - Qian Xiangyun's compensation has varied over the years, with a reported salary of 82.40 million yuan in 2024 [5][6]

Market Overview - The Shanghai Composite Index closed at 3299.76 points, above the annual line, with a change of 0.25% [1] - The total trading volume of A-shares reached 1,121.207 billion yuan [1] Stocks Breaking Annual Line - A total of 106 A-shares have broken above the annual line today [1] - Notable stocks with significant deviation rates include: - Youbuxun: 17.49% deviation, closing price at 15.18 yuan, with a daily increase of 20.00% and turnover rate of 6.57% [1] - Fujilai: 14.53% deviation, closing price at 29.09 yuan, with a daily increase of 20.01% and turnover rate of 30.40% [1] - Chongqing Construction: 8.33% deviation, closing price at 3.01 yuan, with a daily increase of 9.85% and turnover rate of 2.93% [1] Additional Stocks with Minor Deviations - Jiangxi Copper, Meirya, and Laimu Co. have just crossed the annual line with smaller deviation rates [1] - Other stocks with notable performance include: - Changjiang Investment: 7.98% deviation, closing price at 8.01 yuan, with a daily increase of 10.03% [1] - Qingtang City: 7.70% deviation, closing price at 3.78 yuan, with a daily increase of 9.88% [1] - Shenchuan A: 7.45% deviation, closing price at 6.75 yuan, with a daily increase of 9.93% [1] Summary of Stocks with Deviation Rates - A detailed table lists various stocks, their daily change percentages, turnover rates, annual line prices, latest prices, and deviation rates, highlighting the performance of stocks like: - Dongjiang Environmental: 3.70% deviation, closing price at 4.28 yuan, with a daily increase of 10.03% [1] - Feinan Resources: 3.56% deviation, closing price at 19.88 yuan, with a daily increase of 3.92% [1] - The table provides a comprehensive view of the market dynamics and stock performances on the day [2]

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

Market Overview - As of 10:29 AM today, the Shanghai Composite Index is at 3298.26 points, below the six-month moving average, with a change of 0.21% [1] - The total trading volume of A-shares today is 534.203 billion yuan [1] Stocks Performance - A total of 107 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates including: - Hongxing Co., Ltd. with a deviation rate of 8.41% - Yudai Development with a deviation rate of 7.54% - Cuiwei Co., Ltd. with a deviation rate of 7.02% [1] - Other stocks that have just crossed the six-month moving average with smaller deviation rates include: - Bull Group - Inner Mongolia Xinhua - New Energy Group [1] Top Stocks by Deviation Rate - The following stocks have the highest deviation rates from the six-month moving average: - Hongxing Co., Ltd. (9.98% increase, 6.07% turnover rate, latest price 18.19 yuan) - Yudai Development (9.56% increase, 10.62% turnover rate, latest price 4.70 yuan) - Cuiwei Co., Ltd. (9.98% increase, 6.10% turnover rate, latest price 9.15 yuan) [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Hai Xin Food (10.00% increase, 9.46% turnover rate, latest price 4.62 yuan) - Yongtai Transportation (6.27% increase, 9.71% turnover rate, latest price 22.71 yuan) - Shengyibao (9.98% increase, 9.68% turnover rate, latest price 19.84 yuan) [1]

富士莱：一季度净利润同比增长314% 智通财经4月21日电，富士莱(301258.SZ)发布一季报，营业收入1.13亿元，同比增长17.44%；归属于上 市公司股东的净利润为2393.68万元，同比增长313.65%。净利润增加主要系本期投资收益和公允价值变 动收益增加较多所致。 ...